America’s obesity problem has only worsened over the last two decades. From 1999 to 2020, the CDC reports that the incidence of adult obesity in the US has steadily climbed from 31% to 42%. Despite numerous attempts by the weight-loss industry to capitalize on this alarming trend through promoting faddish nutrition plans and flashy fitness regimens, few of these approaches seem to generate a lasting impact. The landmark approval of GLP-1 agonists Wegovy and Saxenda for weight management, along with the increasingly common off-label use of Ozempic and Mounjaro, have created an unexpected bright spot for the pharmaceutical industry. Fueled by viral news of celebrities using these drugs for weight management, interest has surged in recent months. Leveraging occam™ data, we investigate consumer awareness of these medications.
AlphaROC – AI Driven Data Science & Analytics
